Prognostic impact of cytoplasmatic EGFR upregulation in patients with oral squamous cell carcinoma: A pilot study.
OSCC
cytoplasmatic EGFR
epidermal growth factor-receptor
survival
Journal
Molecular and clinical oncology
ISSN: 2049-9450
Titre abrégé: Mol Clin Oncol
Pays: England
ID NLM: 101613422
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
04
02
2020
accepted:
19
09
2020
entrez:
9
11
2020
pubmed:
10
11
2020
medline:
10
11
2020
Statut:
ppublish
Résumé
In various tumors, epidermal growth factor-receptor (EGFR) serves a role in tumorigenesis and has an impact on survival. Usually the EGF-receptor is located on the surface of the cell membrane and is involved in various signaling pathways. The dimerization of EGFR with other ErbB family proteins, such as HER2, is important for the tumor progression. Nevertheless, a second EGFR-associated signaling pathway appears to be important for tumor cells, which is cytoplasmic/nuclear EGFR. The present study examined the influence of membranous or cytoplasmic localized EGFR on the prognosis of patients with oral squamous cell carcinoma (OSCC). Slides from 45 OSCC tumor samples were stained against EGFR using immunohistochemistry and analysed by the Remmele score system. The association with histopathological parameters and survival data was analyzed. Cytoplasmatic EGFR localization was identified as an independent predictive biomarker for overall survival in the examined OSCC cohort according to multivariate Cox regression analysis. Positive cytoplasmatic EGFR staining was correlated with a higher risk of early death (RR=3.0; P=0.035), while membranous EGFR localization did not affect patient survival. To the best of our knowledge, the present study is the first study to demonstrate that cytoplasmatic-localized EGFR is an independent prognostic biomarker for the overall survival of patients with OSCC.
Identifiants
pubmed: 33163183
doi: 10.3892/mco.2020.2158
pii: MCO-0-0-02158
pmc: PMC7642807
doi:
Types de publication
Journal Article
Langues
eng
Pagination
88Informations de copyright
Copyright: © Kappler et al.
Références
Kokubyo Gakkai Zasshi. 2014 Mar;81(1):45-52
pubmed: 24812767
Cancers (Basel). 2020 Aug 12;12(8):
pubmed: 32806571
J Pathol. 1998 Jun;185(2):167-74
pubmed: 9713343
Breast Cancer Res Treat. 2006 Feb;95(3):211-8
pubmed: 16261406
Int J Mol Sci. 2016 Apr 19;17(4):
pubmed: 27104520
Cancer Cell. 2005 Jun;7(6):575-89
pubmed: 15950906
Oral Oncol. 2012 Jan;48(1):67-72
pubmed: 21831696
Pathologe. 1987 May;8(3):138-40
pubmed: 3303008
Oral Dis. 2007 May;13(3):285-90
pubmed: 17448210
Onkologie. 2005 Oct;28 Suppl 4:14-7
pubmed: 16205100
Int J Mol Sci. 2018 Dec 03;19(12):
pubmed: 30513863
Cancer Res. 2005 Jan 1;65(1):338-48
pubmed: 15665312
BMC Cancer. 2017 Aug 25;17(1):572
pubmed: 28841839
Histopathology. 2011 Jun;58(7):1136-47
pubmed: 21438910
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
J Oral Pathol Med. 2012 Aug;41(7):559-67
pubmed: 22417132
Oncol Lett. 2016 Jan;11(1):201-207
pubmed: 26870189
J Transl Med. 2016 Apr 05;14:85
pubmed: 27044404
Head Neck. 2009 Dec;31(12):1544-56
pubmed: 19424974
Int J Biol Markers. 2010 Apr-Jun;25(2):87-92
pubmed: 20544685
Eur J Cancer. 2009 Jun;45(9):1700-8
pubmed: 19332367
Br J Cancer. 2006 Jan 30;94(2):184-8
pubmed: 16434982
Mol Oncol. 2018 Jan;12(1):3-20
pubmed: 29124875
Hepatology. 1991 Jan;13(1):15-20
pubmed: 1988335
Oncol Lett. 2019 Feb;17(2):1551-1558
pubmed: 30675212
Oncotarget. 2016 Nov 8;7(45):74362-74379
pubmed: 27556186
Strahlenther Onkol. 2015 Feb;191(2):180-91
pubmed: 25159136
BMC Bioinformatics. 2019 Aug 22;20(1):434
pubmed: 31438847
Oncol Lett. 2020 Apr;19(4):2809-2816
pubmed: 32218834
Histopathology. 2013 Sep;63(3):297-308
pubmed: 23837466